Content about Dubai

May 22, 2013
Elan buys Austrian drug maker, stake in Dubai drug maker

Irish drug maker Elan is paying about $380 million to buy two drug makers, the company said.

DUBLIN — Irish drug maker Elan Corp. is paying about $380 million to buy one drug maker and a large stake in another, the company said.

Elan announced plans to buy Vienna-based AOP Orphan Pharmaceuticals for about $340 million, a company that specializes in drugs for rare conditions in a variety of areas, including cancer, neurology and metabolic disorders. Elan also paid an initial $40 million to buy a 48% stake in Newbridge Pharmaceuticals, based in Dubai, United Arab Emirates. Elan will have the option to buy the rest of the company for $244 million by 2015.

December 8, 2011
Eli Lilly, Boehringer Ingelheim announce linagliptin trial results

A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

INDIANAPOLIS — A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

Eli Lilly & Co. and Boehringer Ingelheim announced results of a 24-week, open-label arm of a phase-3 study of the investigational drug linagliptin combined with the generic drug metformin, presenting results at the International Diabetes Federation World Diabetes Conference in Dubai.

December 8, 2011
Insulin combination treats low blood sugar in diabetes patients, study finds

A combination of two insulins made by Novo Nordisk reduced abnormally low blood sugar in diabetes patients, according to study results presented at a medical conference.

DUBAI, United Arab Emirates — A combination of two insulins made by Novo Nordisk reduced abnormally low blood sugar in diabetes patients, according to study results presented at a medical conference.

December 7, 2011
Data from Qnexa study presented at World Diabetes Congress

Obese diabetes patients could experience weight loss when taking Vivus' anti-obesity drug, according to an oral presentation at the International Diabetes Federation's World Diabetes Congress in Dubai.

MOUNTAIN VIEW, Calif. — Obese diabetes patients could experience weight loss when taking Vivus' anti-obesity drug, according to an oral presentation at the International Diabetes Federation's World Diabetes Congress in Dubai.